Replies to post #99824 on Biotech Values

[DewDiligence]

I thought I heard Marth say that their immunogenicity data was submitted a month or two after Sandoz and that he felt it was just a matter of timing…

Teva submitted the immunogenicity data to the FDA almost two years ago, so the above is hardly a credible explanation for Teva’s non-approval. I was surprised that Bill Marth pulled such a silly statement from his bag of tricks; that he did shows how little respect he has for Wall Street's biotech analysts.